Compare Nuvalent Inc (NUVL) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Procter & Gamble Co — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Procter & Gamble Co trades at $148.3 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 35.4× Nuvalent Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | PG | |
|---|---|---|
Market Cap | $9.81B | $347.26B |
Sector | Technology | Consumer Staples |
52-Week High | $123.96 | $167.18 |
52-Week Low | $72.16 | $138.10 |
Enterprise Value | $8.52B | $372.74B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Procter & Gamble (PG) trades at $148.12, down 1.23% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent news highlights include a partnership with the WNBA and ongoing supply chain enhancements.
PG offers stable dividend income with a 69-year growth streak, but premium valuations (P/E 21.8) and modest revenue growth pose near-term risks. Analyst consensus is bullish with a $161.71 price target, though competitive pressures and economic sensitivity remain key watchpoints for investors seeking defensive exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
